Hepatocellular carcinoma
Conditions
Interventions
Intervention group (complex intervention group):Receive standard medical care plus complex behavioral interventions
Control group (routine care group):Only standard medical care
Sponsors
The Third Affiliated Hospital of Naval Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically or radiologically confirmed primary hepatocellular carcinoma; 2. BCLC stage B-C, initially assessed as unresectable; 3. Age 18-75 years; 4. ECOG performance status score 0-2; 5. Child-Pugh classification grade A or B (<=9 points); 6. Normal cognitive ability, capable of understanding and following intervention protocols; 7. Both the patient and primary caregiver can use a smartphone and the WeChat platform and are able to complete questionnaires and follow-up tasks; 8. Voluntarily participates in the study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Presence of malignant tumors in other organs; 2. Presence of extrahepatic metastasis; 3. Presence of any of the following severe organic diseases in any organ: (1) Cardiovascular: NYHA class III-IV heart failure, acute coronary syndrome within the past 6 months; (2) Liver: Child-Pugh class C cirrhosis, or ALT/AST >5 times the upper limit of normal; (3) Kidney: eGFR <45 mL/min/1.73m^2 or dialysis-dependent; (4) Respiratory: respiratory failure requiring long-term oxygen therapy; (5) Hematologic: hemoglobin <9 g/dL or platelets <75×10^9/L; 4. History of psychiatric disorders, severe cognitive impairment, or substance abuse; 5. Previous liver transplantation or treatment for malignant liver tumors; 6. Complete thrombosis of the main portal vein; 7. Female patients who are pregnant or breastfeeding; 8. Presence of severe congenital or acquired immunodeficiency; 9. Unwillingness to sign the informed consent form; 10. Other conditions deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year overall survival rate;Progression-Free Survival, PFS;Disease-Free Survival, DFS;Objective Response Rate, ORR;Disease Control Rate, DCR;Treatment-related adverse reactions;Quality of life; | — |
Countries
China
Contacts
Public ContactLiu Hui
The Third Affiliated Hospital of Naval Medical University
Outcome results
None listed